07th week of 2009 patent applcation highlights part 49 |
Patent application number | Title | Published |
20090042853 | PENEM PRODRUGS - Orally bioavailable prodrugs of sulopenem, e.g., | 2009-02-12 |
20090042854 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists - The present invention is directed to certain hexahydrpyrrolidinone compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety. | 2009-02-12 |
20090042855 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME - In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N | 2009-02-12 |
20090042856 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN - A pyridazinone derivative compound shown by the following formula (I): wherein R | 2009-02-12 |
20090042857 | Novel Pharmaceutical - A tissue-selective androgen receptor modulator containing a compound represented by the formula | 2009-02-12 |
20090042858 | LACTAM CONTAINING HCV INHIBITORS - The present invention discloses novel methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including novel oxoazepanylacetamide derivatives useful for viral inhibition. | 2009-02-12 |
20090042859 | SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES - The use of a compound of formula I, wherein Y is a single bond, C═O, C═S or S(O) | 2009-02-12 |
20090042860 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2009-02-12 |
20090042861 | Prophylactic or Therapeutic Agent for Depression or Anxiety Disorder - The present invention provides a prophylactic or therapeutic agent for depression or anxiety disorders, comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide. | 2009-02-12 |
20090042862 | NOVEL COMPOUNDS - The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. | 2009-02-12 |
20090042863 | Therapeutic Agent for Diabetes - The present invention relates to an agent for pancreas protection which contains a combination of a blood glucose lowering drug that does not stimulate insulin secretion and a compound represented by the formula (I) | 2009-02-12 |
20090042864 | PYRAZOLE COMPOUNDS -
This invention relates to pyrazole compounds of formula (I) shown below:
| 2009-02-12 |
20090042865 | DNA-PK INHIBITORS - A compound of formula I: | 2009-02-12 |
20090042866 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control - The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production. | 2009-02-12 |
20090042867 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to substituted 1,2-ethylenediamines of general formula (I), | 2009-02-12 |
20090042868 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitors - Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure. | 2009-02-12 |
20090042869 | SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS - The invention relates to therapeutic target recognition, development, and validation of a compound capable of directly or indirectly modulating TF pre-mRNA splicing in a platelet cell and the use of a platelet TF pre-mRNA splicing modulator for the treatment of a subject suffering from, or thought to be suffering from, disordered coagulation. | 2009-02-12 |
20090042870 | Antimicrobial Composition - An antimicrobial composition suitable for cleaning inanimate surfaces and human skin comprises two or more cationic biocides and two or more biocides which are slower acting than the cationic biocides, wherein each cationic biocide is independently either:
| 2009-02-12 |
20090042872 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same - Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated. | 2009-02-12 |
20090042873 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE - The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): | 2009-02-12 |
20090042874 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS - The invention provides compounds of the Formula: | 2009-02-12 |
20090042875 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF - The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more substituted heterocyclic compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more substituted heterocyclic compounds. The present invention further relates to articles of manufacture and kits comprising one or more substituted heterocyclic compounds. | 2009-02-12 |
20090042876 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors - The present invention relates to inhibitors of protein kinases of formula I: | 2009-02-12 |
20090042877 | Bicyclic Heteroaromatic Derivatives - Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(R | 2009-02-12 |
20090042878 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to thienopyrimidylamines of the general formula I, to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP | 2009-02-12 |
20090042879 | PHTHALAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention provides a novel compound having an excellent PDE4 inhibitory activity and TNF-α production-suppressing activity, and also provides a preventive and therapeutic agent for atopic dermatitis or the like. The present invention includes a novel phthalazinone derivative of the following general structural formula [1] or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising it as an active ingredient. | 2009-02-12 |
20090042880 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES - Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R | 2009-02-12 |
20090042881 | SUBSTITUTED 6-CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2009-02-12 |
20090042882 | SUBSTITUTED ACETAMIDES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to substituted acetamides of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP | 2009-02-12 |
20090042883 | ANTITUMOR AGENT - The present invention provides a therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor which comprises, as an active ingredient, a benzoyl compound represented by General Formula (I): | 2009-02-12 |
20090042884 | Pharmaceutical Compounds - Pyrimidines of formula (I): | 2009-02-12 |
20090042885 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT - An 8-azaprostaglandin represented by formula (I) | 2009-02-12 |
20090042886 | Benzamide Inhibitors of the P2X7 Receptor - The present invention provides benzamide inhibitors of the P2X | 2009-02-12 |
20090042887 | Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents - The present invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on a regular basis. | 2009-02-12 |
20090042888 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors - The present invention describes pyridazinone compounds of formula I | 2009-02-12 |
20090042889 | Pharmaceutical Composition For The Sustained Release Of Hydralazine And Use Thereof As A Support For Cancer Treatment - The invention relates to a sustained release form of hydralazine for use in cancer therapy. Said sustained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy. | 2009-02-12 |
20090042890 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith - Provided herein are Heteroaryl Compounds having the following structure: | 2009-02-12 |
20090042891 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists - The present disclosure relates to a compound of formula (I) | 2009-02-12 |
20090042892 | Cetp Inhibitors - Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B. | 2009-02-12 |
20090042893 | KINASE INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE - Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use. | 2009-02-12 |
20090042894 | NOVEL SPECIES OF ACROCARPOSPORA, A METHOD OF PREPARING IODININ, AND THE USES OF IODININ - The present invention provides a novel species of | 2009-02-12 |
20090042895 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans - Compounds of the Formula: | 2009-02-12 |
20090042896 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS - The invention relates to a compound of formula I | 2009-02-12 |
20090042897 | Chemical Compounds - The present invention relates to novel compounds or a pharmaceutically acceptable salt or solvate thereof, selected from a group consisting of:
| 2009-02-12 |
20090042898 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA - The present invention refert to the use of compounds active on the sigma receptor for the treatment of mechanical allodynia. | 2009-02-12 |
20090042899 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase - Piperazinyl- or piperidinylamine-sulfamic acid amides and their use for the manufacture of a medicament in diseases mediated by the action of steroid sulfatase. | 2009-02-12 |
20090042900 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY -
2,4-Diaminoquinazolines of formula (I)
| 2009-02-12 |
20090042901 | AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH - The present invention relates to an agent for the prevention/therapy of a disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by General Formula (1): | 2009-02-12 |
20090042902 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 2009-02-12 |
20090042903 | PIPERAZINYL-PYRIDINE DERIVATIVES - The present invention relates to compounds of formula I | 2009-02-12 |
20090042904 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments - The present invention relates to substituted phenyl-piperazine compounds of general formula (I), a process for their preparation, medicaments comprising said substituted phenyl-piperazine compounds as well as the use of said substituted phenyl-piperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT | 2009-02-12 |
20090042905 | TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS - The present invention provides triazole derivatives according to formula (I) as ligands of G-protein coupled receptors (GPCR), which are useful for the study of and/or the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, which are mediated by GPCR. | 2009-02-12 |
20090042906 | METHODS FOR TREATING CANCERS ASSOCIATED WITH CONSTITUTIVE EGFR SIGNALING - Aspects of the invention relate to methods and compositions for treating cancers associated with constitutive EGFR signaling. Methods include inhibiting one or more components of the c-Met and/or Axl signaling pathways. Aspects of the invention also relate to methods for determining whether a subject is a candidate for treatment with an inhibitor of a c-Met and/or Axl signaling component. | 2009-02-12 |
20090042907 | Bicyclic aromatic sulfinyl derivatives - The present invention provides compounds of the structure: | 2009-02-12 |
20090042908 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION - The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I | 2009-02-12 |
20090042909 | METHOD OF TREATING DERMATOLOGICAL DISORDERS - A method of treating a dermatological disorder in a subject includes the step of administering a therapeutically effective amount of at least one PPARγ agonist or derivative thereof to the subject. | 2009-02-12 |
20090042910 | QUINOLINE DERIVATIVES FOR TREATING CANCER - The invention concerns quinoline derivatives of Formula I | 2009-02-12 |
20090042911 | Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyri- midin-5-YL](3R,5S)-3, 5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 - The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments. | 2009-02-12 |
20090042912 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE - The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient. | 2009-02-12 |
20090042913 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor - The present invention relates to indolylalkylthienopyrimidylamines of the general formula I, to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP | 2009-02-12 |
20090042914 | Delayed release formulations of 6-mercaptopurine - The present invention provides enterically coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an even further delay such that substantial release of 6-mercaptopurine does not occur until after a certain period of time following passage through the stomach. Such a period of time is preferably at least one hour after passage through the stomach. Following the delay imparted by the enteric coating and optional delay coating, the formulations exhibit better bioavailability and faster dissolution than previous formulations. | 2009-02-12 |
20090042915 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE - [Problems] To provide a medicament, particularly a pharmaceutical composition useful for preventing or treating a variety of diseases caused by infection of a virus of the Herpesviridae family. | 2009-02-12 |
20090042916 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENY- L]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO - The present invention provides novel sulfonylurea salts of a salt of formula (I) | 2009-02-12 |
20090042917 | Aminopyrimidine Derivative and Plant Disease Control Agent for Agricultural or Horticultural Use - A plant disease control agent contains, as an active ingredient, at least one aminopyrimidine derivatives represented by General Formula [I]: | 2009-02-12 |
20090042918 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 - Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R | 2009-02-12 |
20090042919 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS - A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent. | 2009-02-12 |
20090042920 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2009-02-12 |
20090042921 | SPIROINDOLINE DERIVATIVES HAVING INSECTICIDAL PROPERTIES -
An insecticidal compound of formula (I), wherein Y is a single bond, C═O, C═S or S(O) | 2009-02-12 |
20090042922 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS - Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or auto-immune therapeutic abilities. In general, methods of synthesis disclosed herein allow for introduction of a variety of substituents at numerous positions as well as the facile introduction of a beta-lactone ring moiety. The synthetic steps comprise, in preferred embodiments, a tandem Mukaiyama aldol lactonization reaction. Data demonstrating the utility of some of the derivatives as proteasome inhibitors is also disclosed. | 2009-02-12 |
20090042923 | Method of Treating Tumors with Azaxanthones - The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymal nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors. | 2009-02-12 |
20090042924 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics - The present disclosure relates to pyridoindolone derivatives of general formula (I): | 2009-02-12 |
20090042925 | OXIME SUBSTITUTED IMIDAZOQUINOLINES - Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-02-12 |
20090042926 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment - The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included. | 2009-02-12 |
20090042927 | Salts, Prodrugs and Polymorphs of Fab I Inhibitors - In part, the present invention is directed to antibacterial compounds and salts thereof. | 2009-02-12 |
20090042928 | Modulators of muscarinic receptors - The modulator compounds described herein modulate muscarinic receptors and are useful for treating muscarinic receptor mediated diseases. | 2009-02-12 |
20090042929 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors - There is provided a compound having Formula (I) R | 2009-02-12 |
20090042930 | PHARMACEUTICAL COMPOSITIONS CONTAINING CLOPIDOGREL BISULFATE - Provided is a pharmaceutical composition including clopidogrel bisulfate and a pregelatinized starch. The pharmaceutical composition in which the stability of clopidogrel bisulfate is significantly enhanced can be obtained by mixing clopidogrel bisulfate with the pregelatinized starch. | 2009-02-12 |
20090042931 | Tricyclic Angiotensin II Agonists - There is provided compounds of formula I, | 2009-02-12 |
20090042932 | ANTIMICROBIAL PARENTERAL FORMULATION - This invention relates to a parenteral formulation containing an effective amount of the compound of the following formula I: | 2009-02-12 |
20090042933 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor - A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R | 2009-02-12 |
20090042934 | Sulfonyl-Quinoline Derivatives - The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes and intermediates for their preparation, to pharmaceutical compositions containing these compounds and to their use in treatment and/or prevention of conditions which require modulation of mGluR1 and mGluR5 receptors. | 2009-02-12 |
20090042935 | NOVEL IV FORMULATION OF TIPIFARNIB - This invention concerns compositions of tipifarnib, mannitol, and hydroxypropyl-β-cyclodextrin and, suitable for intravenous (IV) administration. The invention further concerns the use of such formulation and processes for preparing such formulations and methods of treating by administering said formulations. | 2009-02-12 |
20090042936 | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation - A composition for treating or controlling an inflammatory anterior-segment disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”). The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in the anterior portion of the eye or a tissue adjacent thereto. | 2009-02-12 |
20090042937 | NITROXIDES FOR USE IN TREATING OR PREVENTING AMYLOID-RELATED DISEASES - Phamaceutical compositions are provided that are useful in treating amyloid protein-related diseases such as Alzheimer's disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that downregulates one or more genes related to the amyloid-related disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of amyloid protein-related diseases. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the amyloid protein-related disease is Alzheimer's disease. In a preferred embodiment, the downregulated genes are genes related to inflammation or oxidative stress. | 2009-02-12 |
20090042938 | Chemical Compounds - The use of a compound of formula (I), Y is a single bond, C═O, C═S or S(O) | 2009-02-12 |
20090042939 | Methods and Compositions Using Cholinesterase Inhibitors - The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine. | 2009-02-12 |
20090042940 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS - The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine. | 2009-02-12 |
20090042941 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects - The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds. | 2009-02-12 |
20090042942 | Muscarinic Receptor Antagonists - The invention provides compounds of formula (I), wherein R | 2009-02-12 |
20090042943 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS - The present invention relates to compounds of formula (I) | 2009-02-12 |
20090042944 | Potassium Channel Inhibitors - The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like. | 2009-02-12 |
20090042945 | Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands - The present invention relates to substituted benzo[d]isoxazol-3-yl-amine compounds, methods for their production, medicaments containing these compounds and the use of these compounds to produce medicaments. | 2009-02-12 |
20090042946 | METHOD AND KIT FOR CONTROLLING BLEEDING - Methods and kits for controlling bleeding from a disrupted blood vessel, wherein a vanilloid receptor agonist is administered to the site of the disruption of the blood vessel in a quantity sufficient to control the bleeding. | 2009-02-12 |
20090042947 | PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING SULFUR - Disclosed herein is a method for the production of disulfide compounds of the formula (I) PAC-S | 2009-02-12 |
20090042948 | Physiologically acceptable salts of 3--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester - The invention relates to new, physiologically acceptable salts of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate. | 2009-02-12 |
20090042949 | Indoles Useful in the Treatment of Inflammation - There is provided compounds of formula I, | 2009-02-12 |
20090042950 | TRANSDERMAL TOPICAL COMPOSITION AND ITS USES - At least one silicone is used to modify the release profile of the active compound(s) in a therapeutic composition for topical application the skin that also comprises at least one penetration enhancer and a fugitive solvent base. | 2009-02-12 |
20090042951 | Blood Pressure Reduction in Salt-Sensitive Hypertension - This invention provides methods and compositions, most preferably pharmaceutical compositions, for treating salt-sensitive hypertension through the inhibition of certain enzymes in the beta-adrenergic pathway that are involved in the regulation of the secretion of water and sodium. These enzymes are cyclic nucleotide phosphodiesterases (PDE) that selectively hydrolyze the second messenger cAMP and, therefore, down-regulate beta-adrenergic signaling. Specifically provided are methods and pharmaceutical compositions for treating salt-sensitive hypertension by inhibiting certain members of the PDE4 family of cyclic nucleotide phosphodiesterases, particularly members of the PDE4B and PDE4D sub-families and, more particularly, the PDE4B1 and PDE4D5 isotypes thereof. | 2009-02-12 |
20090042952 | Sustained Release Composition for Oral Administration of Niacin - A sustained release composition for oral administration of niacin, comprising niacin; a carrier for sustained release composed of a hydrophilic polymer and a hydrophobic polymer; and a pharmaceutically acceptable additive, the hydrophilic polymer being a polyethylene oxide and a natural gum, is capable of maintaining a constant release rate of niacin. | 2009-02-12 |
20090042953 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES - This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I: | 2009-02-12 |